Baird Financial Group’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $45.4K | Buy |
+10,532
| New | +$45.4K | ﹤0.01% | 1758 |
|
|
2025
Q1 | – | Sell |
-2,987
| Closed | -$30.3K | – | 1802 |
|
|
2024
Q4 | $30.3K | Buy |
2,987
+467
| +19% | +$4.74K | ﹤0.01% | 1742 |
|
|
2024
Q3 | $31.4K | Buy |
2,520
+67
| +3% | +$834 | ﹤0.01% | 1735 |
|
|
2024
Q2 | $31.9K | Buy |
2,453
+1,066
| +77% | +$13.9K | ﹤0.01% | 1741 |
|
|
2024
Q1 | $31.4K | Buy |
1,387
+467
| +51% | +$10.6K | ﹤0.01% | 1739 |
|
|
2023
Q4 | $11.9K | Hold |
920
| – | – | ﹤0.01% | 1702 |
|
|
2023
Q3 | $18.5K | Hold |
920
| – | – | ﹤0.01% | 1698 |
|
|
2023
Q2 | $24.7K | Sell |
920
-878
| -49% | -$23.6K | ﹤0.01% | 1676 |
|
|
2023
Q1 | $105K | Buy |
1,798
+525
| +41% | +$30.6K | ﹤0.01% | 1655 |
|
|
2022
Q4 | $65K | Buy |
1,273
+60
| +5% | +$3.06K | ﹤0.01% | 1665 |
|
|
2022
Q3 | $99K | Buy |
1,213
+85
| +8% | +$6.94K | ﹤0.01% | 1669 |
|
|
2022
Q2 | $76K | Sell |
1,128
-8
| -0.7% | -$539 | ﹤0.01% | 1752 |
|
|
2022
Q1 | $126K | Sell |
1,136
-185
| -14% | -$20.5K | ﹤0.01% | 1775 |
|
|
2021
Q4 | $127K | Buy |
1,321
+142
| +12% | +$13.7K | ﹤0.01% | 1848 |
|
|
2021
Q3 | $103K | Buy |
1,179
+48
| +4% | +$4.19K | ﹤0.01% | 1841 |
|
|
2021
Q2 | $175K | Buy |
1,131
+90
| +9% | +$13.9K | ﹤0.01% | 1706 |
|
|
2021
Q1 | $164K | Buy |
1,041
+14
| +1% | +$2.21K | ﹤0.01% | 1655 |
|
|
2020
Q4 | $239K | Buy |
1,027
+91
| +10% | +$21.2K | ﹤0.01% | 1452 |
|
|
2020
Q3 | $205K | Buy |
936
+44
| +5% | +$9.64K | ﹤0.01% | 1404 |
|
|
2020
Q2 | $253K | Buy |
892
+29
| +3% | +$8.23K | ﹤0.01% | 1356 |
|
|
2020
Q1 | $249K | Sell |
863
-4
| -0.5% | -$1.15K | ﹤0.01% | 1260 |
|
|
2019
Q4 | $249K | Buy |
+867
| New | +$249K | ﹤0.01% | 1393 |
|